pentobarbital will minimize the level or impact of elbasvir/grazoprevir by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. The therapeutic impact of elbasvir/grazoprevir can be lowered if coadministered with powerful CYP3A inducers which is therefore contraindicated.pentobarbital will decrease the level or effect of docetaxe